Monocyte tissue factor levels in XXXX with @entity5 : an association between @entity5 presence and progression.

@entity1 @entity32 @entity1494 @entity5 @entity150 @entity547 @entity1486 @entity71978 @entity526
OBJECTIVE: To examine the hypothesis that increased monocyte tissue factor ( @entity71978 ) levels may reflect urological @entity5 presence and progression. @entity1 , SUBJECTS AND METHODS: Using a two-stage kinetic chromogenic assay, @entity71978 levels were measured in 60 controls (normal subjects [60] and @entity1 awaiting @entity547 repair or cholecystectomy [60]), @entity1 with benign and @entity1494 (73), or prostate (81), and in @entity1 with and without recurrent @entity1494 (30). The levels were assessed under fresh resting conditions (baseline) and after incubation for 6 h without (unstimulated) and with (stimulated) @entity526 endotoxin. Each benign disease group was subdivided into inflammatory and non-inflammatory categories. RESULTS: @entity1 with bladder and prostate malignancy showed significantly higher @entity71978 levels than did each control for baseline and stimulated cells. The benign inflammatory groups for both organs had significantly higher @entity71978 levels than had each control for baseline cells. There was no difference between malignant and benign inflammatory groups. Stimulated @entity71978 levels showed better discrimination between the study groups. The @entity71978 levels were associated with histological @entity5 progression, serum @entity1486 level and static bone scan images. Levels were also higher in @entity1 with @entity150 recurrence than in those with a normal check cystoscopy. CONCLUSION: Stimulated @entity71978 levels are raised in @entity32 compared with controls and @entity1 with non-inflammatory conditions, and give maximal discrimination between these groups. @entity71978 levels showed an association with @entity5 grade and other markers of @entity5 progression.
